Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glycosylated rituximab
- Development stage
- Preclinical
- Lead developer
- IDEC
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Glycosylated rituximab is an anti-CD20 monoclonal antibody developed by Fountain Biopharma. It is designed as a biosimilar or biobetter version of rituximab, featuring engineered glycosylation patterns intended to alter or enhance its effector functions, such as antibody-dependent cellular cytotoxicity (ADCC). The drug targets the CD20 antigen expressed on the surface of B cells, leading to their depletion, which is a key therapeutic strategy in managing autoimmune conditions. Its primary development focus is the treatment of Rheumatoid Arthritis.
- Other names
- glyco-rituximabrituximab biosimilar
02
Targets
Beyond the preview
Go deeper on Glycosylated rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glycosylated rituximab.